ISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair

Abstract The use of poly(ADP-ribose) polymerase inhibitors (PARPi) has proven largely successful in targeting BRCA1/2 -mutated tumours. However, the emergence of PARPi-resistant disease can reduce the efficacy of this treatment, posing significant challenges in the clinic. Here, we use multiple models of BRCA1 -/- cells and patient-derived xenografts (PDXs) that have been treated with PARPi until they no longer responded to the drug, to characterise genomic and transcriptomic alterations specific to PARPi resistance. We find that abrogation of TP53BP1 expression occurs spontaneously during prolonged PARPi treatment, alongside TP53BP1 genomic deletions and promoter methylation. Additionally, innate immune response genes, including ISG15 and factors of the ISGylation machinery are upregulated in PARPi-resistant cells and tumours. We demonstrate that ISG15 inhibition re-sensitises PARPi-resistant cells to the drug and, conversely, that ISG15 overexpression in BRCA1 -/- cells promotes PARPi resistance. Mechanistically, BRCA1 -/- PARPi-resistant cells rely on ISG15 for replication fork progression and restart of stalled forks and for DNA double-strand break (DSB) repair via homologous recombination (HR). Our results indicate that complex ISG15 interactions with DNA replication/repair factors can drive PARPi resistance in BRCA1-deficient cancer cells and that targeting ISG15 has the potential to overcome PARPi resistance.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-12
DOI
https://doi.org/10.1038/s41467-026-78554-1
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair

Giuliana De Gregoriis, Florian J. Groelly, Adán Pinto-Fernández, Flaminia Pedretti et al.
Nature Communications
PARP inhibition in cancer therapy
article

ISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair

Giuliana De Gregoriis, Florian J. Groelly, Adán Pinto-Fernández, Flaminia Pedretti, Teressa Paulsen, Birbal Prasad, Violeta Serra, Andrea Herencia-Ropero, Rebecca A. Dagg, Madalena Tarsounas, Simeon D. Draganov, Yuri Seung
article en

Abstract

Abstract The use of poly(ADP-ribose) polymerase inhibitors (PARPi) has proven largely successful in targeting BRCA1/2 -mutated tumours. However, the emergence of PARPi-resistant disease can reduce the efficacy of this treatment, posing significant challenges in the clinic. Here, we use multiple models of BRCA1 -/- cells and patient-derived xenografts (PDXs) that have been treated with PARPi until they no longer responded to the drug, to characterise genomic and transcriptomic alterations specific to PARPi resistance. We find that abrogation of TP53BP1 expression occurs spontaneously during prolonged PARPi treatment, alongside TP53BP1 genomic deletions and promoter methylation. Additionally, innate immune response genes, including ISG15 and factors of the ISGylation machinery are upregulated in PARPi-resistant cells and tumours. We demonstrate that ISG15 inhibition re-sensitises PARPi-resistant cells to the drug and, conversely, that ISG15 overexpression in BRCA1 -/- cells promotes PARPi resistance. Mechanistically, BRCA1 -/- PARPi-resistant cells rely on ISG15 for replication fork progression and restart of stalled forks and for DNA double-strand break (DSB) repair via homologous recombination (HR). Our results indicate that complex ISG15 interactions with DNA replication/repair factors can drive PARPi resistance in BRCA1-deficient cancer cells and that targeting ISG15 has the potential to overcome PARPi resistance.

Nature Communications
Universitat Autònoma de Barcelona (ES), University of Oxford (GB), Centro de Investigación Biomédica en Red de Cáncer (ES), Vall d'Hebron Institute of Oncology (ES)
Cancer Research UK, University of Oxford, Chinese Academy of Medical Sciences, Universität Zürich
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon